Novartis India launches Pluvicto for prostate cancer treatment

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach for metastatic prostate cancer. The therapy will be available through select hospitals and nuclear medicine centers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f1EnHrB
via IFTTT